Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation

Blood

Volumn 103, Issue 5, 2004, Pages 1869-1875

  Montesinos Rongen, Manuel ^b   Van Roost, Dirk ^b   Schaller, Carlo ^b   Wiestler, Otmar D ^b   Deckert, Martina ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; TRANSCRIPTION FACTOR PAX5;

ARTICLE; B CELL LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; DISEASE ASSOCIATION; GENE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PIM1 GENE; PRIORITY JOURNAL; RHOH GENE; SEQUENCE ANALYSIS; SOMATIC HYPERMUTATION;

EID: 1442307976     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1465     Document Type: Article

References (22)

1. Gatter KC, Wamke RA. Diffuse large cell lymphoma. In: Jaffe ES, Harris NL, Stein H, eds. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:171-174.
2. Schlegel U, Schmidt-Wolf IG, Deckert M. Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci. 2000;181:1-12.
3. Montesinos-Rongen M, Zühlke-Jenisch R, Gesk S, et al. Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exp Neurol. 2002;61:926-933.
4. Montesinos-Rongen M, Küppers R, Schlüter D, et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol. 1999;155:2077-2086.
5. Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 1998;92:1011-1019.
6. Thompsett AR, Ellison DW, Stevenson FK, Zhu D. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood. 1999;94:1738-1746.
7. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341-346.
8. Akasaka H, Akasaka T, Kurata M, et al. Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res. 2000;60:2335-2341.
9. Nagarajan L, Louie E, Tsujimoto Y, ar-Rushdi A, Huebner K, Croce CM. Localization of the human pim oncogene (PIM) to a region of chromosome 6 involved in translocations in acute leukemias. Proc Natl Acad Sci U S A. 1986;83:2556-2560.
10. Johnston JM, Carroll WL. c-myc Hypermutation in Burkitt's lymphoma. Leuk Lymphoma. 1992;8:431-439.
11. Preudhomme C, Roumier C, Hildebrand MP, et al. Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma. Oncogene. 2000;19:2023-2032.
12. Ohno H, Ueda C, Akasaka T. The t(9;14)(p13; q32) translocation in B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2000;36:435-445.
13. Gronbaek K, Straten PT, Ralfkiaer E, et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood. 1998;92:3018-3024.
14. Arnheim N, Erlich H. Polymerase chain reaction strategy. Annu Rev Biochem. 1992;61:131-156.
15. Erlich HA, Gelfand D, Sninsky JJ. Recent advances in the polymerase chain reaction. Science. 1991;252:1643-1651.
16. Ionov Y, Le X, Tunquist BJ, et al. Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res. 2003;23:167-178.
17. Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood. 2003;102:1833-1841.
18. Seeberger H, Starostik P, Schwarz S, et al. Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development. Lab Invest. 2001;81:977-986.
19. Müschen M, Rajewsky K, Krönke M, Küppers R. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol. 2002;23:75-80.
20. Kurth J, Perniok A, Schmitz R, et al. Lack of deleterious somatic mutations in the CD95 gene of plasmablasts from systemic lupus erythematosus patients and autoantibody-producing cell lines. Eur J Immunol. 2002;32:3785-3792.
21. Stevenson FK, Spellerberg MB, Chapman CJ, Hamblin TJ. Differential usage of an autoantibody-associated VH gene, VH4-21, by human B-cell tumors. Leuk Lymphoma. 1995;16:379-384.
22. Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood. 2003;101:2914-2923.